| Home | E-Submission | Sitemap | Contact Us |  
J Korean Cancer Assoc > Volume 22(3); 1990 > Article
Journal of the Korean Cancer Association 1990;22(3): 532-539.
침윤성 흉선종에 대한 Cyclophosphamide , Adriamycin , Cisplatin ( CAP ) 복합화학요법
박영석, 임영혁, 강원기, 서창인, 이기형, 정경해, 김흥태, 허대석, 방영주, 김노경
Cyclophosphamide , Adriamycin and Cisplatin ( CAP ) Combination Chemotherapy for Invasive Thymoma
Young Suk Park, Young Hyuk Im, Won Ki Kang, Chang In Suh, Kee Hyung Lee, Kyung Hae Jung, Heung Tae Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim
Between October 1985 and January 1990, the combination chemotherapy with cyclophosphamide, adriamycin and cisplatin (CAP) has been administered in 16 patients with invasive, recurrent or metastatic thymoma. Among 14 evaluable patients, 1 patient(7%) achieved a complete response and 4 patients (29%) had a partial response. The 4 year overall survival rates were 56.7% with a median follow-up of 11.5 months. The mast frequent hematologic toxicity was leukopenia (15.9%) and nonhematologic toxicity (WHO criteria; grade II) were alopecia (80%) and nausea/vomiting (66.7%). The CAP regimen is effective and well tolerated for the treatment of invasive thymoma, and further study is needed to confirm the relative effectiveness of CAP regimen in comparison with other regimens and to find out the prognostic factors related to response rate and survival
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI